ERBB2 and neoplasm: Traditionally, pathologic determinations of tumor size, lymph node status, endocrine receptor status, and human epidermal growth factor receptor 2 (HER2) status have driven prognostic predictions and, ultimately, adjuvant therapy recommendations for patients with early stage breast cancer.